NCT05256225 2026-04-16
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
12 trialsNCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT04759248 2025-09-09
ATREZZO
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06589830 2025-05-15
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
Phase 2 Not yet recruiting